140 related articles for article (PubMed ID: 24463666)
1. Value of symptom-triggered diagnostic evaluation for ovarian cancer.
Andersen MR; Lowe KA; Goff BA
Obstet Gynecol; 2014 Jan; 123(1):73-79. PubMed ID: 24463666
[TBL] [Abstract][Full Text] [Related]
2. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
[TBL] [Abstract][Full Text] [Related]
3. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Buys SS; Partridge E; Black A; Johnson CC; Lamerato L; Isaacs C; Reding DJ; Greenlee RT; Yokochi LA; Kessel B; Crawford ED; Church TR; Andriole GL; Weissfeld JL; Fouad MN; Chia D; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hartge P; Pinsky PF; Zhu CS; Izmirlian G; Kramer BS; Miller AB; Xu JL; Prorok PC; Gohagan JK; Berg CD;
JAMA; 2011 Jun; 305(22):2295-303. PubMed ID: 21642681
[TBL] [Abstract][Full Text] [Related]
4. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
[TBL] [Abstract][Full Text] [Related]
5. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
[TBL] [Abstract][Full Text] [Related]
6. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.
Stirling D; Evans DG; Pichert G; Shenton A; Kirk EN; Rimmer S; Steel CM; Lawson S; Busby-Earle RM; Walker J; Lalloo FI; Eccles DM; Lucassen AM; Porteous ME
J Clin Oncol; 2005 Aug; 23(24):5588-96. PubMed ID: 16110018
[TBL] [Abstract][Full Text] [Related]
7. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.
Partridge EE; Greenlee RT; Riley TL; Commins J; Ragard L; Xu JL; Buys SS; Prorok PC; Fouad MN
Obstet Gynecol; 2013 Jan; 121(1):25-31. PubMed ID: 23262924
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
[TBL] [Abstract][Full Text] [Related]
9. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.
Bosse K; Rhiem K; Wappenschmidt B; Hellmich M; Madeja M; Ortmann M; Mallmann P; Schmutzler R
Gynecol Oncol; 2006 Dec; 103(3):1077-82. PubMed ID: 16904167
[TBL] [Abstract][Full Text] [Related]
10. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
[TBL] [Abstract][Full Text] [Related]
11. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Henderson JT; Webber EM; Sawaya GF
JAMA; 2018 Feb; 319(6):595-606. PubMed ID: 29450530
[TBL] [Abstract][Full Text] [Related]
12. Results from four rounds of ovarian cancer screening in a randomized trial.
Partridge E; Kreimer AR; Greenlee RT; Williams C; Xu JL; Church TR; Kessel B; Johnson CC; Weissfeld JL; Isaacs C; Andriole GL; Ogden S; Ragard LR; Buys SS;
Obstet Gynecol; 2009 Apr; 113(4):775-782. PubMed ID: 19305319
[TBL] [Abstract][Full Text] [Related]
13. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
[TBL] [Abstract][Full Text] [Related]
14. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
Meeuwissen PA; Seynaeve C; Brekelmans CT; Meijers-Heijboer HJ; Klijn JG; Burger CW
Gynecol Oncol; 2005 May; 97(2):476-82. PubMed ID: 15863147
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer screening.
van Nagell JR; Gallion HH; Pavlik EJ; DePriest PD
Cancer; 1995 Nov; 76(10 Suppl):2086-91. PubMed ID: 8635005
[TBL] [Abstract][Full Text] [Related]
16. Benefits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer.
Varras M
Clin Exp Obstet Gynecol; 2004; 31(2):85-98. PubMed ID: 15266758
[TBL] [Abstract][Full Text] [Related]
17. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
Lu KH; Skates S; Hernandez MA; Bedi D; Bevers T; Leeds L; Moore R; Granai C; Harris S; Newland W; Adeyinka O; Geffen J; Deavers MT; Sun CC; Horick N; Fritsche H; Bast RC
Cancer; 2013 Oct; 119(19):3454-61. PubMed ID: 23983047
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors.
Zanetta G; Rota S; Lissoni A; Meni A; Brancatelli G; Buda A
Gynecol Oncol; 2001 Apr; 81(1):63-6. PubMed ID: 11277651
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.
Buys SS; Partridge E; Greene MH; Prorok PC; Reding D; Riley TL; Hartge P; Fagerstrom RM; Ragard LR; Chia D; Izmirlian G; Fouad M; Johnson CC; Gohagan JK;
Am J Obstet Gynecol; 2005 Nov; 193(5):1630-9. PubMed ID: 16260202
[TBL] [Abstract][Full Text] [Related]
20. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
